TKNO

+ Watchlist + Portfolio

Alpha Teknova, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.86
52-Week Range: $1.91 – $9.48
Market Cap: $482.66M
P/E (TTM): —
EPS (TTM): -0.31
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 7.71
PEG Ratio: —
Return on Equity: -24.19%
Return on Assets: -9.28%
Gross Margin: 34.60%
Operating Margin: -23.72%
Profit Margin: -38.37%
Current Ratio: 4.49
Debt/Equity: 0.44
Total Debt: $27.41M
Free Cash Flow: $-735.25K
Revenue Growth: 18.50%
Earnings Growth: —
Enterprise Value: $492.63M

TKNO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$41.42M	$36.68M	$37.74M	$40.52M
Cost of Revenue	$23.94M	$26.39M	$30.51M	$27.08M
Gross Profit	$17.48M	$10.30M	$7.23M	$13.44M
Research & Development	$7.74M	$5.57M	$2.76M	$2.20M
Selling, General & Admin	$37.45M	$34.78M	$29.47M	$27.07M
Operating Expenses	$46.33M	$41.49M	$33.38M	$30.42M
Operating Income	-$28.86M	-$31.20M	-$26.15M	-$16.98M
EBITDA	-$25.69M	-$30.59M	-$19.57M	-$10.15M
Pretax Income	-$49.39M	-$37.08M	-$26.83M	-$17.20M
Income Tax	-$1.92M	-$298.00K	-$88.00K	$58.00K
Net Income	-$47.47M	-$36.78M	-$26.75M	-$17.26M
Diluted EPS	-1.69	-1.16	-0.57	-0.32
Diluted Shares	28.08M	31.82M	46.75M	53.48M

TKNO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$42.24M	$28.48M	$3.71M	$5.91M
Receivables	$4.28M	$3.95M	$4.31M	$4.62M
Inventory	$12.25M	$11.59M	$6.80M	$7.05M
Current Assets	$61.14M	$45.66M	$42.78M	$34.51M
Total Assets	$152.26M	$128.59M	$118.77M	$103.58M
Current Liabilities	$10.88M	$8.88M	$11.21M	$7.54M
Long-Term Debt	$21.98M	$13.25M	$9.44M	$13.12M
Total Debt	$42.31M	$30.46M	$30.17M	$28.27M
Total Liabilities	$52.38M	$38.55M	$36.38M	$34.81M
Retained Earnings	-$55.01M	-$91.79M	-$118.53M	-$135.79M
Shareholders' Equity	$99.89M	$90.04M	$82.39M	$68.78M
Working Capital	$50.27M	$36.78M	$31.57M	$26.97M
Net Debt	—	—	$9.78M	$7.21M

TKNO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.40M	-$18.81M	-$12.39M	-$8.65M
Capital Expenditure	-$28.15M	-$7.93M	-$1.13M	-$1.15M
Free Cash Flow	-$55.55M	-$26.75M	-$13.52M	-$9.79M
Depreciation & Amortisation	$3.17M	$5.66M	$6.58M	$6.34M
Stock-Based Compensation	$3.71M	$4.14M	$3.67M	$3.43M
Investing Cash Flow	-$28.15M	-$7.74M	-$27.27M	$10.70M
Financing Cash Flow	$10.27M	$12.80M	$14.89M	$151.00K
Net Change in Cash	-$45.28M	-$13.75M	-$24.78M	$2.20M

TKNO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$9.79M	$10.29M	$10.45M	$9.98M	$11.08M	$12.19M
Cost of Revenue	$6.79M	$6.30M	$7.25M	$6.74M	$7.29M	$7.30M
Gross Profit	$3.01M	$3.98M	$3.21M	$3.24M	$3.78M	$4.88M
Research & Development	$552.00K	$581.00K	$542.00K	$522.00K	$609.00K	$554.00K
Selling, General & Admin	$7.13M	$6.50M	$6.39M	$7.04M	$7.19M	$6.93M
Operating Expenses	$7.97M	$7.37M	$7.22M	$7.85M	$8.08M	$7.78M
Operating Income	-$4.96M	-$3.39M	-$4.02M	-$4.61M	-$4.30M	-$2.89M
EBITDA	-$2.90M	-$1.80M	-$2.43M	-$3.03M	-$2.71M	-$1.29M
Pretax Income	-$4.62M	-$3.55M	-$4.21M	-$4.82M	-$4.51M	-$3.14M
Income Tax	$22.00K	$19.00K	$79.00K	-$62.00K	$47.00K	$30.00K
Net Income	-$4.64M	-$3.57M	-$4.29M	-$4.76M	-$4.55M	-$3.17M
Diluted EPS	-0.09	-0.07	-0.08	-0.09	-0.08	-0.06
Diluted Shares	53.42M	53.45M	53.52M	53.54M	53.61M	53.63M

TKNO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.38M	$3.28M	$3.20M	$5.91M	$4.31M	$6.00M
Receivables	$5.62M	$5.14M	$5.13M	$4.62M	$5.67M	$5.41M
Inventory	$6.57M	$7.61M	$6.91M	$7.05M	$6.87M	$6.91M
Current Assets	$39.73M	$38.06M	$36.56M	$34.51M	$31.67M	$30.82M
Total Assets	$113.99M	$110.49M	$107.63M	$103.58M	$98.66M	$95.88M
Current Liabilities	$7.04M	$6.48M	$6.94M	$7.54M	$6.90M	$6.87M
Long-Term Debt	$12.99M	$13.03M	$13.08M	$13.12M	$13.17M	$13.22M
Total Debt	$29.34M	$28.97M	$28.98M	$28.27M	$27.83M	$27.41M
Total Liabilities	$35.39M	$34.43M	$34.98M	$34.81M	$33.73M	$33.28M
Retained Earnings	-$123.18M	-$126.75M	-$131.03M	-$135.79M	-$140.34M	-$143.51M
Shareholders' Equity	$78.61M	$76.06M	$72.65M	$68.78M	$64.92M	$62.60M
Working Capital	$32.69M	$31.58M	$29.63M	$26.97M	$24.78M	$23.95M
Net Debt	$9.61M	$9.76M	$9.87M	$7.21M	$8.86M	$7.21M

TKNO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.10M	-$2.10M	-$1.98M	-$462.00K	-$3.36M	-$471.00K
Capital Expenditure	-$206.00K	-$207.00K	-$387.00K	-$348.00K	-$221.00K	-$125.00K
Free Cash Flow	-$4.31M	-$2.31M	-$2.37M	-$810.00K	-$3.58M	-$596.00K
Depreciation & Amortisation	$1.58M	$1.59M	$1.59M	$1.58M	$1.58M	$1.59M
Stock-Based Compensation	$852.00K	$950.00K	$850.00K	$777.00K	$695.00K	$622.00K
Investing Cash Flow	$3.82M	$2.03M	$1.64M	$3.21M	$1.84M	$1.95M
Financing Cash Flow	-$52.00K	-$28.00K	$268.00K	-$37.00K	-$88.00K	$224.00K
Share Repurchases	$0.00	$0.00	—	—	—	—
Net Change in Cash	-$331.00K	-$101.00K	-$72.00K	$2.71M	-$1.61M	$1.70M

Market Snapshot

About

Alpha Teknova, Inc. is a provider of critical reagents that enable the discovery, development, and production of biopharmaceutical products. The company manufactures molecular biology reagents, cell culture media, and custom products for life sciences research and clinical applications. Teknova serves pharmaceutical, biotech, academic, and government research organizations.